Related Experiment Videos
Tumor lysis syndrome: pathogenesis and management
D P Jones1, H Mahmoud, R W Chesney
1Department of Pediatrics, University of Tennessee, Memphis, USA.
Pediatric Nephrology (Berlin, Germany)
|April 1, 1995
Summary
Tumor lysis syndrome causes metabolic disturbances like hyperuricemia and acute renal failure in cancer patients. Understanding its pathogenesis and treatment is crucial for patient outcomes.
Area of Science:
- Oncology
- Nephrology
- Internal Medicine
Background:
- Tumor lysis syndrome (TLS) is a oncologic emergency characterized by metabolic derangements.
- TLS arises from the rapid breakdown of malignant cells, often in lymphoproliferative disorders.
- Metabolic disturbances include hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia, potentially leading to acute kidney injury.
Purpose of the Study:
- To elucidate the pathogenesis of tumor lysis syndrome.
- To discuss current therapeutic strategies for managing TLS.
- To highlight the link between TLS metabolic alterations and acute renal failure.
Main Methods:
- Review of existing literature on TLS pathogenesis.
- Analysis of metabolic disturbances associated with TLS.
- Discussion of clinical factors influencing TLS severity.
Main Results:
- TLS is characterized by severe metabolic disturbances secondary to cell lysis.
- Hyperuricemia and hyperphosphatemia are key contributors to oliguric acute renal failure in TLS.
- TLS severity is influenced by chemotherapy, cell lysis magnitude, and patient's hydration status.
Conclusions:
- TLS necessitates prompt recognition and management due to potential for acute renal failure.
- Understanding the pathogenesis is key to developing effective therapeutic strategies.
- Multifaceted patient factors influence the development and severity of TLS.